StockNews.AI
BAX
StockNews.AI
180 days

Baxter Reports Fourth-Quarter and Full-Year 2024 Results

1. Baxter delivered robust Q4 and FY2024 performance; announced Q1 and FY2025 guidance. 2. CEO highlighted growing momentum, enhancing stakeholder value; strategic milestones were noted.

Earnings
+9.18%Current Return
VS
-2.04%S&P 500
$30.8202/20 07:42 AM EDTEvent Start
$33.6502/21 02:25 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The strong quarterly outcomes and optimistic guidance suggest improved investor sentiment, as similar past medtech results have spurred stock rallies. Historical precedents from earnings beats indicate immediate positive market reactions.

How important is it?

Earnings updates and strategic milestone announcements are crucial for Baxter. These updates have historically led to significant near-term price movements.

Why Short Term?

Earnings releases typically trigger rapid market responses, with short-term price adjustments driven by guidance and financial performance.

Related Companies

MDTBDX
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2024, and provided its financial guidance for first-quarter and full-year 2025. “Our 2024 performance and related strategic milestones reflect Baxter's growing momentum in our pursuit of enhanced value for patients, healthcare providers, customers and shareholders,” said Brent Shafer, chair and interim chief executive officer.

Related News